Multiple Myeloma: all 3,712 studies

Page 26 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.

• Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma MultipleStatus unknownNCT02976272
• Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT02971410Early Phase 1
• Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple MyelomaTerminatedNCT02967276Phase 2
• Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
• Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)Status unknownNCT02955810Phase 1
• A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)CompletedNCT02955550Phase 1
• Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant RecoveryCompletedNCT02955043Not applicable
• A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT02954796Phase 1
• A Clinical Research of BCMA-Targeted CAR-T in B Cell MalignanciesStatus unknownNCT02954445Phase 1/2
• Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of ImprovementTerminatedNCT02952573Phase 2
• Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingNCT02952508Phase 2
• A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer TreatmentWithdrawnNCT02951117Phase 1
• Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic LeukemiaCompletedNCT02948283Phase 1
• A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in SpainCompletedNCT02946333
• A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseCompletedNCT02922543
• A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mgCompletedNCT02921828
• A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesCompletedNCT02921802
• Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin LymphomaCompletedNCT02920697Phase 1
• Comparison of Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02918695
• A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell TransplantationCompletedNCT02918331Phase 1
• Prevalence of Ocular Disorders in Multiple Myeloma (MM-OO-16)CompletedNCT02917239
• Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATGCompletedNCT02916979Phase 1
• Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple MyelomaStatus unknownNCT02916420Phase 3
• PRospective Multiple Myeloma Impact StudyActive, not recruitingNCT02911571Not applicable
• Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.Active, not recruitingNCT02909036Phase 1
• An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical PracticeCompletedNCT02902900
• CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician ChoiceTerminatedNCT02900248
• Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)Active, not recruitingNCT02899052Phase 2
• Back Pain Prevention in Multiple Myeloma Using an External Spinal BraceCompletedNCT02898064Not applicable
• Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple MyelomaTerminatedNCT02897830Phase 2
• Quality of Life the Danish Multiple Myeloma PatientsCompletedNCT02892383
• Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance StrategyCompletedNCT02891811Phase 2
• Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803CompletedNCT02890758Phase 1
• Role of CX3CR1-expressing Cells in Hematologic MalignancyStatus unknownNCT02885623
• Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic MalignaciesCompletedNCT02885038
• MMRF Molecular Profiling ProtocolActive, not recruitingNCT02884102
• Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantActive, not recruitingNCT02861417Phase 2
• Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple MyelomaCompletedNCT02861287
• Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70CompletedNCT02858999Phase 2
• Early Patient Access Treatment Use Protocol CA204-220No longer availableNCT02856438
• Familial DysglobulinemiaCompletedNCT02853214Not applicable
• Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic TherapyCompletedNCT02852837Phase 1
• Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)CompletedNCT02851056Early Phase 1
• A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine ClearanceCompletedNCT02849444
• A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic NeoplasmsCompletedNCT02842229
• Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell ProductTerminatedNCT02840110
• BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)CompletedNCT02834364Phase 2
• A Study of Denosumab in Multiple Myeloma Patients With Renal InsufficiencyCompletedNCT02833610Phase 2
• A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With MyelomaCompletedNCT02831686Phase 1
• Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02811978Phase 3
• A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple MyelomaCompletedNCT02811822Phase 1
• Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,PanobinostatWithdrawnNCT02802163Phase 1/2
• Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple MyelomaCompletedNCT02800954Not applicable
• Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.Status unknownNCT02797041
• Vinorelbine and Gemcitabine in MyelomaCompletedNCT02791373Phase 2
• Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic ToolStatus unknownNCT02791217
• Longterm Follow-up of Subjects Treated With bb2121CompletedNCT02786511
• Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCTWithdrawnNCT02786485Phase 1
• Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic MyelomaTerminatedNCT02784483Phase 1
• Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple MyelomaTerminatedNCT02773550Phase 4
• A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple MyelomaTerminatedNCT02756728Phase 1/2
• Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple MyelomaWithdrawnNCT02756663Phase 2
• Daratumumab in Combination With ATRACompletedNCT02751255Phase 1/2
• A Diagnostic Screening Trial Seeking AL Amyloidosis Very EarlyCompletedNCT02741999
• Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])CompletedNCT02741544
• Adherence to Lenalidomide Treatment in Multiple Myeloma - Prevalence, Characteristics and Clinical SignificanceStatus unknownNCT02733224
• To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple MyelomaTerminatedNCT02732925Not applicable
• Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell TransplantationCompletedNCT02719821Not applicable
• Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabCompletedNCT02719613Phase 2
• A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple MyelomaActive, not recruitingNCT02718833Phase 2
• Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot StudyCompletedNCT02697383Phase 1
• Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaCompletedNCT02697344Phase 1
• Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02692339
• Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor MobilizersWithdrawnNCT02682953Phase 2
• Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple MyelomaNo longer availableNCT02666209
• Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
• URMC Related Haplo-identical Donor BMTCompletedNCT02660281Phase 1
• Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple MyelomaActive, not recruitingNCT02659293Phase 3
• Study of bb2121 in Multiple MyelomaCompletedNCT02658929Phase 1
• GO-203-2C + Bortezomib For Relapsed Or Refractory MMWithdrawnNCT02658396Phase 1
• Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple MyelomaCompletedNCT02655458Phase 1
• Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsCompletedNCT02649790Phase 1/2
• Multiparametric Imaging in Multiple MyelomaCompletedNCT02646085Phase 1
• Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseCompletedNCT02636010Phase 2
• Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple MyelomaWithdrawnNCT02628704Phase 2
• Multiple Myeloma Minimal Residual DiseaseCompletedNCT02627261
• Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple MyelomaCompletedNCT02626481Phase 2
• Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple MyelomaStatus unknownNCT02624440Phase 2
• A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02616640Phase 1
• A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple MyelomaCompletedNCT02609230Phase 1
• A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive DiseaseCompletedNCT02608515
• Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple MyelomaWithdrawnNCT02605356Phase 1/2
• Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell TransplantWithdrawnNCT02589860
• STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTSCompletedNCT02586038Phase 2
• Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT02579824Phase 1
• UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD CombinationWithdrawnNCT02578121Phase 2
• PDD vs PAD to Treat Initially Diagnosed MMStatus unknownNCT02577783Phase 4
• Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic MalignanciesCompletedNCT02576496Phase 1
• GEM-CLARIDEX: Ld vs BiRdStatus unknownNCT02575144Phase 3
• Clarithromycin in Multiple Myeloma Induction TherapyTerminatedNCT02573935Phase 2

← Multiple Myeloma overview